Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04588077 · ClinicalTrials.gov registry record · Phase 4
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
A Phase 4 study of Cirrhosis, Liver and Hepatitis B, sponsored by Mercy Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT04588077 is a Phase 4 study of Cirrhosis, Liver and Hepatitis B that is actively recruiting participants, run by Mercy Medical Center. The registered enrollment target is 200 participants, below the 236-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04588077, a Phase 4 study of Cirrhosis, Liver and Hepatitis B, is actively recruiting participants, sponsored by Mercy Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.
Conditions Studied
Interventions
- BIOLOGICAL Heplisav-B Injectable Product, 2-dose regimen
- BIOLOGICAL Heplisav-B Injectable Product, 3-dose regimen
Study Locations (1)
Maryland
- Mercy Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2020-09-14 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04588077
The ClinicalTrials.gov registry entry for NCT04588077 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 236-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (15% lower). The listed sponsor is Mercy Medical Center, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cirrhosis, Liver appearing as the primary indexed condition, and to 2 interventions - of which Heplisav-B Injectable Product, 2-dose regimen is the first listed.
NCT04588077 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT04588077 about?
NCT04588077 is a clinical study titled "Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis". Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.
What is the current status of trial NCT04588077?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2020-09-14. Estimated completion is 2028-12-01.
What conditions does trial NCT04588077 study?
This clinical trial studies the following conditions: Cirrhosis, Liver, Hepatitis B, Chronic Liver Disease.
What interventions are being tested in trial NCT04588077?
The interventions under investigation include: Heplisav-B Injectable Product, 2-dose regimen (BIOLOGICAL), Heplisav-B Injectable Product, 3-dose regimen (BIOLOGICAL).
Who is sponsoring clinical trial NCT04588077?
This trial is sponsored by Mercy Medical Center, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04588077 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis, Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prophylactic Antibiotics in Admitted Cirrhotics
COMPLETED · Phase 4
-
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
RECRUITING · Phase 1
-
Measuring Patient Reported Needs in Outpatient Liver Disease Management
RECRUITING
-
Molecular Mechanism of Exercise in Cirrhosis
RECRUITING · NA
-
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
RECRUITING · Phase 2
-
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.